COMPASS Pathways Plc - American (CMPS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.36
- Estimate
- -$0.33
- Surprise
- -6.6%
- Score today
- 5.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
COMPASS Pathways Plc - American (CMPS) reported a wider loss than forecast — diluted EPS of -$0.36 against the -$0.33 estimate (a 6.6% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CMPS Sell at 5.6/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -6.6% surprise compares with a -13.4% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Concentration risk — Pipeline: COMP360 psilocybin treatment (sole clinical program)
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $13.43
- Price target
- $21.38
- Stop
- $12.40
- Upside to target
- +59.2%
- Reward-to-risk
- 4.0:1
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
CMPS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Care Facilities
- Market cap
- $1.85B
- P/E (fwd)
- -9.3
- 52-week range
- $4.29–$15.40
- Off 52-week high
- 12.8%
- RSI (14)
- 67
- Volume vs avg
- 0.73×
- Score today
- 5.6/10